Evidence map›Paper›PMID 38678493›Full record

ArticleSurgery today2024

Prognostic factors and significance of postoperative adjuvant chemotherapy in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy followed by gastrectomy.

Masaaki Motoori, Kentaro Kishi, Kazuyoshi Yamamoto, Atsushi Takeno, Hisashi Hara, Kohei Murakami, Takuya Hamakawa, Yujiro Nakahara, Toru Masuzawa, Takeshi Omori and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Surgery today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masaaki MotooriDepartment of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka, 558-8558, Japan. mmotoori@gh.opho.jp.
Kentaro KishiDepartment of Surgery, Osaka Police Hospital, Osaka, Japan.
Kazuyoshi YamamotoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Atsushi TakenoDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Hisashi HaraDepartment of Digestive Surgery, Osaka International Cancer Institute, Osaka, Japan.
Kohei MurakamiDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
Takuya HamakawaDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Yujiro NakaharaDepartment of Surgery, Osaka Police Hospital, Osaka, Japan.
Toru MasuzawaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
Takeshi OmoriDepartment of Digestive Surgery, Osaka International Cancer Institute, Osaka, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kazumasa FujitaniDepartment of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka, 558-8558, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn Japan, gastrectomy with D2 lymph node dissection and postoperative adjuvant chemotherapy are the standard treatments for locally advanced gastric cancer. Neoadjuvant chemotherapy (NAC) is not affected by postgastrectomy syndromes or postoperative complications. This multicenter retrospective study investigated the prognostic factors and significance of postoperative adjuvant chemotherapy in patients with advanced gastric cancer who underwent NAC followed by gastrectomy.

methodsConsecutive patients (n = 221) with advanced gastric cancer who underwent NAC followed by curative surgery were enrolled in this study. Prognostic factors including postoperative adjuvant chemotherapy were investigated using univariate and multivariate analyses.

resultsA multivariate analysis revealed that pathological lymph node metastasis (ypN) status and postoperative adjuvant chemotherapy were independent prognostic factors for the overall and relapse-free survival. Forty-five patients (20.4%) did not receive postoperative adjuvant chemotherapy. There were no significant differences between patients with and without adjuvant chemotherapy for all factors, except age. The most common reason for not undergoing postoperative adjuvant chemotherapy was a poor condition (n = 23).

conclusionsypN status and postoperative adjuvant chemotherapy were independent prognostic factors in gastric cancer patients who underwent NAC followed by curative gastrectomy. It is important to maintain the patient's condition during NAC and the perioperative period so that they can receive postoperative adjuvant chemotherapy.

Indexed as

GastrectomyNeoadjuvant TherapyStomach NeoplasmsAdultAgedAged, 80 and overChemotherapy, AdjuvantFemaleHumansLymphatic MetastasisLymph Node ExcisionMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateGastric cancerNeoadjuvant chemotherapyPostoperative adjuvant chemotherapyPrognostic factor

Identifiers

PMID38678493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.